drugset / Trial / NCT03258359
Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety of autologous T cells that have been immunized ex vivo with patient-specific MDS stem cell neoantigens in patients with MDS.
Timeline
- Start
- 2018-01-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PACTN | Cell therapy | 3e+06 cells/kg | — |
| Subject | PACTN | Cell therapy | 1e+07 cells/kg | — |
| Subject | PACTN | Cell therapy | 3e+07 cells/kg | — |